---

Management of hypertriglyceridemia-induced pancreatitis – A review of updates from the past decade

Full Text PDF Share on Facebook Share on Twitter

---

Review Article

Author Details : Fateen Ata*, Adeel Ahmad Khan, Zohaib Yousaf, Ammar Chapra

Volume : 1, Issue : 1, Year : 2022

Article Page : 2-5

Suggest article by email

Abstract

Hypertriglyceridemia-induced acute-pancreatitis (HTG-AP) is an important etiology of acute pancreatitis (AP). The treatment includes general management of AP with bowel rest, analgesia, and venous thromboembolism prophylaxis. Specific treatment of HTG-AP focuses on reducing serum triglyceride (TG) levels. Various modalities have been used, including heparin infusion, insulin infusion, plasmapheresis, and double filtration plasmapheresis (DFPP). However, the extent to which TG reduction translates into a clinical response remains unclear. This review highlights the emerging evidence on the management of HTG-AP. Insulin therapy and plasmapheresis remain treatment options to reduce TG. DFPP is an emerging treatment modality to reduce TG levels in patients with AP. However, to what extent this translates into a better clinical response is yet to be answered in large and prospective study designs.

Keywords: Hypertriglyceridemia, Pancreatitis, Triglycerides, Hypertriglyceridemia-induced acute pancreatitis

How to cite : Ata F, Khan A A, Yousaf Z, Chapra A, Management of hypertriglyceridemia-induced pancreatitis – A review of updates from the past decade. Yemen J Med 2022;1(1):2-5

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International, which allows others to remix, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.